Evidence map›Paper›PMID 36609449›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.

Min Deng, Long Zhang, Wenying Zheng, Jiale Chen, Nan Du, Meiqi Li, Weiqing Chen, Yonghong Huang, Ning Zeng, Yuanbin Song and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. NAT10-mediated acCellular & molecular biology letters · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. The NAT10/acCell communication and signaling : CCS · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Functional roles and mechanisms of NAT10-mediated RNA acFrontiers in cell and developmental biology · 2026
    Review
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Min Deng *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Long Zhang *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Wenying Zheng *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Jiale ChenAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Nan DuSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
Meiqi LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Weiqing ChenAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Yonghong HuangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of "Translational Medicine On Malignant Tumor Treatment", Guangzhou, 510095, China.
Ning ZengFirst Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangdong Provincial Clinical and Engineering Technology Center of Digital Medicine, Guangzhou, 510280, China. zjyygd_zn@163.com.
Yuanbin SongSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. songyb@sysucc.org.cn.
Yongming ChenSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. chenyongm@sysucc.org.cn.
Guangzhou Medical University · CNState Key Laboratory of Oncology in South ChinaSouthern Medical University · CNSun Yat-sen University · CN

Funding

Medical Science and Technology Foundation of Guangdong Province A2020184National Natural Science Foundation of China 81972771National Natural Science Foundation of China 82173062Natural Science Foundation of Guangdong Province 2018B0303110015
6 · The paper itself

Abstract

backgroundN4-acetylcytidine (ac4C), a widespread modification in human mRNAs that is catalyzed by the N-acetyltransferase 10 (NAT10) enzyme, plays an important role in promoting mRNA stability and translation. However, the biological functions and regulatory mechanisms of NAT10-mediated ac4C were poorly defined.

methodsac4C mRNA modification status and NAT10 expression levels were analyzed in gastric cancer (GC) samples and compared with the corresponding normal tissues. The biological role of NAT10-mediated ac4C and its upstream and downstream regulatory mechanisms were determined in vitro and in vivo. The therapeutic potential of targeting NAT10 in GC was further explored.

resultsHere, we demonstrated that both ac4C mRNA modification and its acetyltransferase NAT10 were increased in GC, and increased NAT10 expression was associated with disease progression and poor patient prognosis. Functionally, we found that NAT10 promoted cellular G2/M phase progression, proliferation and tumorigenicity of GC in an ac4C-depedent manner. Mechanistic analyses demonstrated that NAT10 mediated ac4C acetylation of MDM2 transcript and subsequently stabilized MDM2 mRNA, leading to its upregulation and p53 downregulation and thereby facilitating gastric carcinogenesis. In addition, Helicobacter pylori (Hp) infection contributed to NAT10 induction, causing MDM2 overexpression and subsequent p53 degradation. Further investigations revealed that targeting NAT10 with Remodelin showed anti-cancer activity in GC and augmented the anti-tumor activity of MDM2 inhibitors in p53 wild-type GC.

conclusionsThese results suggest the critical role of NAT10-mediated ac4C modification in GC oncogenesis and reveal a previously unrecognized signaling cascade involving the Hp-NAT10-MDM2-p53 axis during GC development.

Indexed as

Helicobacter pyloriStomach NeoplasmsAcetylationAcetyltransferasesHumansN-Terminal AcetyltransferasesProto-Oncogene Proteins c-mdm2RNA, MessengerTumor Suppressor Protein p53AcetyltransferasesMDM2 protein, humanNAT10 protein, humanN-Terminal AcetyltransferasesProto-Oncogene Proteins c-mdm2RNA, MessengerTumor Suppressor Protein p53Gastric cancerHelicobacter pyloriMDM2N4-acetylcytidineN-acetyltransferase 10p53

Identifiers

PMID36609449
PMCPMC9817303
OpenAlexW4313647386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.